Concepedia

Author

Petros Nikolinakos

University Cancer and Blood Center

Also Known As

Nikolinakos, Petros, P G Nikolinakos, P Nikolinakos, P. Nikolinakos, Petros G. Nikolinakos, Petros Nikolinakos, Robyn Young

91

Publications

6.8K

Citations

29

H-Index

49

Concepts

All Affiliations

University Cancer and Blood CenterThe University of Texas MD Anderson Cancer CenterUniversity of GeorgiaWashington University in St. LouisSarah Cannon
PN

About

Petros Nikolinakos is an author at University Cancer and Blood Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

19

3.7K

2

Cell Biology

6

6

424

3

Health Sciences

1

1

16

4

Public Health

1

1

24

5

Biostatistics

1

1

24

Petros Nikolinakos

×

42

Publications

6.7K

Citations

28

H-Index

YearCitations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen,

The Lancet

2019

2.1K

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Dirix, István Takács, Guy Jérusalem,

Breast Cancer Research and Treatment

2017

739

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill,

PLoS ONE

2015

708

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen,

The Lancet Oncology

2020

662

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

David Waterhouse, Edward B. Garon, Jason C. Chandler,

Journal of Clinical Oncology

2020

223

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph Zinner, Coleman K. Obasaju, David R. Spigel,

Journal of Thoracic Oncology

2014

171

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Tibor Csőszi, Marina Maglakelidze, Robert J. Hoyer,

Annals of Oncology

2019

161

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang,

Journal of Thoracic Oncology

2020

149

HIF2α cooperates with RAS to promote lung tumorigenesis in mice

William Y. Kim, Samanthi A. Perera, Bing Zhou,

Journal of Clinical Investigation

2009

139

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

Alexa B. Schrock, Viola W. Zhu, Wen-Son Hsieh,

Journal of Thoracic Oncology

2018

133

Page 1